Metabolomics and lipidomics analyses by H-1 nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis

Metabolomics and lipidomics analyses by H-1 nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis

Author Tasic, Ljubica Google Scholar
Pontes, Joao G. M. Google Scholar
Carvalho, Michelle S. Autor UNIFESP Google Scholar
Cruz, Guilherme Google Scholar
Dal Mas, Carolines Autor UNIFESP Google Scholar
Sethi, Sumit Autor UNIFESP Google Scholar
Pedrini, Mariana Autor UNIFESP Google Scholar
Rizzo, Lucas B. Autor UNIFESP Google Scholar
Zeni-Graiff, Maiara [UNIFESP Google Scholar
Asevedo, Elson Autor UNIFESP Google Scholar
Lacerda, Acioly L. T. Autor UNIFESP Google Scholar
Bressan, Rodrigo A. Autor UNIFESP Google Scholar
Poppi, Ronei Jesus Google Scholar
Brietzke, Elisa Autor UNIFESP Google Scholar
Hayashi, Mirian A. F. Autor UNIFESP Google Scholar
Abstract Using H-1 NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabolic differences between schizophrenia patients (SCZ) compared to healthy controls (HCs). HCs and SCZ patients underwent clinical interview using the Structured Clinical Interview for DSM Disorders (SCID). SCZ patients were further assessed by Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, Global Assessment of Functioning Scale (GAF), and Clinical Global Impressions Scale (CGI). Using the principal component analysis (PCA) and supervised partial least-squares discriminate analysis (PLS-DA) in obtained NMR data, a clear group separation between HCs and SCZ patients was achieved. Interestingly, all metabolite compounds identified as exclusively present in the SCZ group, except for the gamma-aminobutyric acid (GABA), were never previously associated with mental disorders. Although the initial perception of an absence of obvious biological link among the different key molecules exclusively observed in each group, and no identification of any specific pathway yet, the present work represents an important contribution for the identification of potential biomarkers to inform diagnosis, as it was possible to completely separate the affected SCZ patients from HCs, with no outliers or exceptions. In addition, the data presented here reinforced the role of the modulation of glycolysis pathway and the loss of GABA intemeuron/hyperglutamate hypothesis in SCZ. (C) 2016 Elsevier B.V. All rights reserved.
Keywords Schizophrenia
xmlui.dri2xhtml.METS-1.0.item-coverage Amsterdam
Language English
Sponsor Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
National Council of Technological and Scientific Development (CNPq)
Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
Grant number FAPESP: 2014/18938-8
FAPESP: 2013/13392-4
CNPq: 477760/2010-4
CNPq: 557753/2010-4
CNPq: 508113/2010-5
CNPq: 311815/2012-0
CNPq: 475739/2013-2
CNPq: 454234/2014-7
Date 2017
Published in Schizophrenia Research. Amsterdam, v. 185, p. 182-189, 2017.
ISSN 0920-9964 (Sherpa/Romeo, impact factor)
Publisher Elsevier Science Bv
Extent 182-189
Type Article
Web of Science ID WOS:000403561000026

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account